Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0. It has been cited 6 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Holden Comprehensive Cancer Center (HCCC)
Grant: R37CA238274
Holden Comprehensive Cancer Center (HCCC)
Grant: R01CA184101
Holden Comprehensive Cancer Center (HCCC)
Grant: R01CA99908
Holden Comprehensive Cancer Center (HCCC)
Grant: R50CA243786
National Institutes of Health
Grant: 1R50CA243786-01
Core-based Scientist specializing in high throughput screening for early drug discovery, target identification and systems biology analysis of cancer
National Institutes of Health
Grant: 1R37CA238274-01A1
Restoring Progestin Sensitivity in Endometrial Cancer
National Institutes of Health
Grant: 5R01CA184101-02
MTDH regulates Fanconi anemia repair pathway to mediate drug resistance
National Institutes of Health
Grant: 7R01CA099908-19
Targeted Therapy for Endometrial Cancer
Fields of Study
Keywords
Sustainable Development Goals